Your browser doesn't support javascript.
loading
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan, Raffit; Sharon, Elad; Thomas, Anish; Zhang, Jingli; Ling, Alexander; Miettinen, Markku; Kreitman, Robert J; Steinberg, Seth M; Hollevoet, Kevin; Pastan, Ira.
Affiliation
  • Hassan R; Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer ; 120(21): 3311-9, 2014 Nov 01.
Article in En | MEDLINE | ID: mdl-24989332
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Glutamates / Guanine / Lung Neoplasms / Mesothelioma / Antibodies, Monoclonal Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pleural Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Glutamates / Guanine / Lung Neoplasms / Mesothelioma / Antibodies, Monoclonal Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Year: 2014 Type: Article